Skip to main content
SpringerLink
Log in

Ipilimumab: little effect on HRQOL despite toxicities

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. health-related quality of life

References

  1. Coens C, et al. Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. Lancet Oncology : 2 Feb 2017. Available from: URL: http://doi.org/10.1016/S1470-2045(17)30015-3.

  2. Brundage M, et al. Adjuvant ipilimumab for stage III melanoma: the patient voice. Lancet Oncology : 2 Feb 2017. Available from: URL: http://doi.org/10.1016/S1470-2045(17)30003-7/

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ipilimumab: little effect on HRQOL despite toxicities. PharmacoEcon Outcomes News 772, 26 (2017). https://doi.org/10.1007/s40274-017-3774-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-3774-5

Search

Navigation